July 8, 2015 Applying Regulatory Science to Develop Safe and Effective Medicines for Neonates Offringa M, Davis JM, Turner MA, Ward R, Bax R, Maldonado S, Sinha V, McCune SK, Zajicek A, Daniel K. Benjamin J, Bucci-Rechtweg C
FDA: Guidance for Industry Duchenne Muscular Dystrophy Developing Drugs for Treatment Over the Spectrum of Disease
January 6, 2015 Patient-Reported Outcomes In Cancer Drug Development And US Regulatory Review: Perspectives From Industry, The Food And Drug Administration, And The Patient
European Medicines Agency Qualifies ‘Hollow Fiber System’ For Anti-Tuberculosis Drug Development February 6, 2015 European Medicines Agency Qualifies ‘Hollow Fiber System’ For Anti-Tuberculosis Drug Development Provides maj
January 12, 2014 Regulatory Science Needs for Neonates: A Call for Neonatal Community Collaboration and Innovation
January 12, 2014 Modeling And Simulation For Medical Product Development And Evaluation: Highlights From The FDA-C-Path-ISOP 2013 Workshop
